Cue Biopharma (CUE) Net Margin (2018 - 2025)
Historic Net Margin for Cue Biopharma (CUE) over the last 8 years, with Q3 2025 value amounting to 343.09%.
- Cue Biopharma's Net Margin fell 891300.0% to 343.09% in Q3 2025 from the same period last year, while for Sep 2025 it was 525.1%, marking a year-over-year decrease of 691500.0%. This contributed to the annual value of 429.4% for FY2024, which is 4720200.0% up from last year.
- As of Q3 2025, Cue Biopharma's Net Margin stood at 343.09%, which was down 891300.0% from 285.61% recorded in Q2 2025.
- In the past 5 years, Cue Biopharma's Net Margin registered a high of 95.58% during Q4 2021, and its lowest value of 50800.0% during Q2 2022.
- Its 5-year average for Net Margin is 4946.68%, with a median of 705.07% in 2024.
- Per our database at Business Quant, Cue Biopharma's Net Margin tumbled by -504247200bps in 2022 and then skyrocketed by 498627400bps in 2023.
- Cue Biopharma's Net Margin (Quarter) stood at 95.58% in 2021, then plummeted by -9763bps to 9426.49% in 2022, then soared by 92bps to 709.88% in 2023, then grew by 16bps to 592.83% in 2024, then surged by 42bps to 343.09% in 2025.
- Its Net Margin stands at 343.09% for Q3 2025, versus 285.61% for Q2 2025 and 2881.0% for Q1 2025.